These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 38925972)
1. Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy. Yagi Y; Kanemasa Y; Sasaki Y; Goto S; Yamamura Y; Masuda Y; Fujita K; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Morita Y; Tamura T; Nakamura S; Okuya T; Matsuda S; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Shimoyama T J Clin Exp Hematop; 2024; 64(2):107-118. PubMed ID: 38925972 [TBL] [Abstract][Full Text] [Related]
2. Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation. Molina JC; Steinberg SM; Yates B; Lee DW; Little L; Mackall CL; Shalabi H; Shah NN Transplant Cell Ther; 2022 Jan; 28(1):31.e1-31.e9. PubMed ID: 34687939 [TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338 [TBL] [Abstract][Full Text] [Related]
4. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy. Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W Front Immunol; 2021; 12():755549. PubMed ID: 34777367 [TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis. Shargian L; Raanani P; Yeshurun M; Gafter-Gvili A; Gurion R Br J Haematol; 2022 Sep; 198(5):838-846. PubMed ID: 35765220 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review. Tian L; Li C; Sun J; Zhai Y; Wang J; Liu S; Jiang Y; Wu W; Xing D; Lv Y; Guo J; Xu H; Sun H; Li Y; Li L; Zhao Z Front Immunol; 2022; 13():1041177. PubMed ID: 36733398 [TBL] [Abstract][Full Text] [Related]
7. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study. Bastos-Oreiro M; Gutierrez A; Iacoboni G; López Corral L; Reguera JL; Abrisqueta P; Delgado J; Terol MJ; Hernani R; Martínez N; Ortíz V; Bailen R; Gomez-Centurión I; Caballero A; Sanz J; Guerra Domínguez L; Luzardo H; Mussetti A; Jiménez-Ubieto A; Sancho JM; Sureda A; Pérez A; Barba P; Kwon M; Martín García-Sancho A Transplant Cell Ther; 2023 Dec; 29(12):747.e1-747.e10. PubMed ID: 37659694 [TBL] [Abstract][Full Text] [Related]
8. Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration. Sýkorová A; Folber F; Polgárová K; Móciková H; Ďuraš J; Steinerová K; Obr A; Heindorfer A; Ladická M; Lukáčová Ľ; Čellárová E; Plameňová I; Belada D; Janíková A; Trněný M; Jančárková T; Procházka V; Vranovský A; Králiková M; Vydra J; Smolej L; Drgoňa Ľ; Sedmina M; Čermáková E; Pytlík R Cancer Med; 2024 Sep; 13(17):e70138. PubMed ID: 39248284 [TBL] [Abstract][Full Text] [Related]
9. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y Front Immunol; 2020; 11():564099. PubMed ID: 33329526 [TBL] [Abstract][Full Text] [Related]
10. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS; Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989 [TBL] [Abstract][Full Text] [Related]
11. Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis. Puckrin R; Stewart DA; Shafey M Transplant Cell Ther; 2022 Apr; 28(4):218.e1-218.e4. PubMed ID: 35123117 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis. Derigs P; Bethge WA; Krämer I; Holtick U; von Tresckow B; Ayuk F; Penack O; Vucinic V; von Bonin M; Baldus C; Mougiakakos D; Wulf G; Schnetzke U; Stelljes M; Fante M; Schroers R; Kroeger N; Dreger P; Transplant Cell Ther; 2023 Dec; 29(12):750-756. PubMed ID: 37709204 [TBL] [Abstract][Full Text] [Related]
13. Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma. Liu W; Liu W; Zou H; Chen L; Huang W; Lv R; Xu Y; Liu H; Shi Y; Wang K; Wang Y; Xiong W; Deng S; Yi S; Sui W; Peng G; Ma Y; Wang H; Lv L; Wang J; Wei J; Qiu L; Zheng W; Zou D J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631712 [TBL] [Abstract][Full Text] [Related]
14. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805 [TBL] [Abstract][Full Text] [Related]
15. Combination of chidamide and PD-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy. Wang Z; Xu H; Mei Y; Xiao M; Cao Y; Huang L; Yang Z; Zhang Y; Han Z; Zheng M; Hong Z Int Immunopharmacol; 2024 May; 133():112014. PubMed ID: 38615378 [TBL] [Abstract][Full Text] [Related]
17. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells. Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X Front Immunol; 2022; 13():879030. PubMed ID: 35558072 [TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers. Ahmed N; Sun F; Teigland C; Kilgore KM; Mohammadi I; Chambers J; Dieyi C; Feng C; Osborn J; Fu C; Gergis U Transplant Cell Ther; 2024 Jul; 30(7):714-725. PubMed ID: 38697294 [TBL] [Abstract][Full Text] [Related]
19. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Shadman M; Ahn KW; Kaur M; Lekakis L; Beitinjaneh A; Iqbal M; Ahmed N; Hill B; Hossain NM; Riedell P; Gopal AK; Grover N; Frigault M; Brammer J; Ghosh N; Merryman R; Lazaryan A; Ram R; Hertzberg M; Savani B; Awan F; Khimani F; Ahmed S; Kenkre VP; Ulrickson M; Shah N; Kharfan-Dabaja MA; Herrera A; Sauter C; Hamadani M Blood Cancer J; 2024 Jul; 14(1):108. PubMed ID: 38977682 [TBL] [Abstract][Full Text] [Related]
20. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia. Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P Front Immunol; 2021; 12():605766. PubMed ID: 34025637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]